The present invention provides a universal system that detects cancer cells at all stages including early developmental stages as well as matured cancerous tumors. The system relates to monitoring the environment surrounding abnormally metabolizing cells, e.g., predominantly glycolytic cells, cancerous cells, precancerous cells, and/or cells with reduced mitochondrial Electron Transport Chain activity. Nanosensors detect chemical signatures of the organic compounds released by cancer cells into bodily fluids or to the air to detect cancerous or precancerous metabolisms in samples such as urine, saliva, sweat, blood or breath. Treatments provided in recognition of the signature metabolic changes occurring in cancer cells target the abnormal metabolism generally with special emphasis relating to changed mitochondrial metabolism and cell survivability. The treatments include, but are not limited to: therapeutic compositions and methods for treating, delaying, slowing or preventing one or more cancers.